Evidence map›Paper›PMID 32007145›Full record

ArticleLancet (London, England)2020

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Roujian Lu, Xiang Zhao, Juan Li, Peihua Niu, Bo Yang, Honglong Wu, Wenling Wang, Hao Song, Baoying Huang, Na Zhu and 25 more

10 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Lancet (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 10 registered trials, which are not on this map. Cited by 6,229 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6,229citing papers in PubMed, 6 pooled it
295.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04343768 phase2completednot on this map

An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial

TypeinterventionalSponsorShahid Beheshti University of Medical SciencesRan2020 to 2020Enrolled60ConditionsCOVID-19ArmsHydroxychloroquine, Lopinavir / Ritonavir, Interferon Beta-1A, Interferon Beta-1B
NCT04352556 unknown statusnot on this map

SARS-CoV-2 Infection in Patients With Hematological Malignancies: the Italian Hematology Alliance

TypeobservationalSponsorOspedale di Circolo - Fondazione MacchiRan2020 to 2022Enrolled250ConditionsSARS-CoV-2 Infection, Hematological Malignancies
NCT04402203 phase2 / phase3unknown statusnot on this map

Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh

TypeinterventionalSponsorBangladesh Medical Research Council (BMRC)Ran2020 to 2020Enrolled50ConditionsCOVID-19, Favipiravir (Favipira)ArmsFavipiravir, Only Standard Treatment
NCT04407182 phase2completednot on this map

Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients in Teodoro Maldonado Carbo Specialty's Hospital Infected and Diagnosed by SARS-Cov-2 With COVID-19

TypeinterventionalSponsorCatalysis SLRan2020 to 2020Enrolled60ConditionsCovid-19, Sars-CoV2, Diabete Mellitus, CardiopathyArmsViusid and Asbrip
NCT04414904 withdrawnnot on this map

Determining the Reproductive Health of Men Post-COVID-19 Infection

TypeobservationalSponsorImperial College LondonRan2020 to 2020Enrolled0ConditionsInfertility, Male, Testosterone DeficiencyArmsExposure: Covid-19 infection
NCT04420260 nacompletednot on this mapstarted 2021, after this paper: background citation

Scheme of Primary Prevention of Infection by COVID-19, in Workers: Phase II Controlled Clinical Trial, to be Carried Out in Medellín-Antioquia

TypeinterventionalSponsorUnidad de Investigación Genética MolecularRan2021 to 2021Enrolled152ConditionsCOVIDArmsGroup A: oropharygeal spray and immunostimulant emulsion, Group D:Placebo oropharyngeal spray + Placebo taken PO
NCT04516746 phase3completednot on this map

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19

TypeinterventionalSponsorAstraZenecaRan2020 to 2023Enrolled32,450ConditionsCOVID-19, SARS-CoV-2ArmsAZD1222, Placebo
NCT04568525 nacompletednot on this map

Microwave Radiation for Early Diagnostics of Pneumonia in Patients With COVID-19

TypeinterventionalSponsorKyrgyz State Medical AcademyRan2020 to 2020Enrolled195ConditionsCovid19ArmsPassive Microwave Radiometry
NCT04987853 unknown statusnot on this mapstarted 2021, after this paper: background citation

Assessment of the Influence of Clinical, Functional, Immunological, and Genetic Factors on the Severity of the Course of Coronavirus Infection With SARS-CoV-2 and Post Covid Syndrome

TypeobservationalSponsorNational Research Center for Cardiac Surgery, KazakhstanRan2021 to 2023Enrolled300ConditionsCovid19, Corona Virus InfectionArmsClinical and functional analysis, Neurological analysis, Immunological analysis:, Genetic analysis:
NCT04998253 early_phase1completednot on this map

A Randomized Pilot Clinical Trial of the Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction of Sevoflurane in Patient's Whit ARDS Secondary to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2)

TypeinterventionalSponsorUnidad Temporal COVID-19 en Centro CitibanamexRan2020 to 2021Enrolled24ConditionsHypoxic Pulmonary Vasoconstriction, Hypoxemia, Acute Respiratory Distress Syndrome, SARS-CoV-2 Acute Respiratory DiseaseArmsEffects in oxygenation and hypoxic pulmonary vasoconstriction
3 · Its place in the literature

Who cites it

6,229 citing papers in PubMed, 6 syntheses or guidelines pooled it, 12,526 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

6,169 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors at 9 institutions in 2 countries.

Roujian LuNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Xiang ZhaoNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Juan LiKey Laboratory of Etiology and Epidemiology of Emerging Infectious Diseases in Universities of Shandong, Shandong First Medical University and Shandong Academy of Medical Sciences, Tai'an, China.
Peihua NiuNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Bo YangDivision for Viral Disease Detection, Hubei Provincial Center for Disease Control and Prevention, Wuhan, China.
Honglong WuBGI PathoGenesis Pharmaceutical Technology, Shenzhen, China.
Wenling WangNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Hao SongResearch Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, China.
Baoying HuangNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Na ZhuNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Yuhai BiChinese Academy of Sciences Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China; Center for Influenza Research and Early-warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), Chinese Academy of Sciences, Beijing, China.
Xuejun MaNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Faxian ZhanDivision for Viral Disease Detection, Hubei Provincial Center for Disease Control and Prevention, Wuhan, China.
Liang WangChinese Academy of Sciences Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China; Center for Influenza Research and Early-warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), Chinese Academy of Sciences, Beijing, China.
Tao HuKey Laboratory of Etiology and Epidemiology of Emerging Infectious Diseases in Universities of Shandong, Shandong First Medical University and Shandong Academy of Medical Sciences, Tai'an, China.
Hong ZhouKey Laboratory of Etiology and Epidemiology of Emerging Infectious Diseases in Universities of Shandong, Shandong First Medical University and Shandong Academy of Medical Sciences, Tai'an, China.
Zhenhong HuCentral Theater, People's Liberation Army General Hospital, Wuhan, China.
Weimin ZhouNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Li ZhaoNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Jing ChenKey Laboratory of Laboratory Medicine, Ministry of Education, and Zhejiang Provincial Key Laboratory of Medical Genetics, Institute of Medical Virology, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, China.
Yao MengNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Ji WangNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Yang LinBGI PathoGenesis Pharmaceutical Technology, Shenzhen, China.
Jianying YuanBGI PathoGenesis Pharmaceutical Technology, Shenzhen, China.
Zhihao XieBGI PathoGenesis Pharmaceutical Technology, Shenzhen, China.
Jinmin MaBGI PathoGenesis Pharmaceutical Technology, Shenzhen, China.
William J LiuNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Dayan WangNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Wenbo XuNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Edward C HolmesMarie Bashir Institute for Infectious Diseases and Biosecurity, School of Life and Environmental Sciences and School of Medical Sciences, University of Sydney, Sydney, NSW, Australia.
George F GaoNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China; Chinese Academy of Sciences Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China; Center for Influenza Research and Early-warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), Chinese Academy of Sciences, Beijing, China.
Guizhen WuNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Weijun ChenBGI PathoGenesis Pharmaceutical Technology, Shenzhen, China.
Weifeng ShiKey Laboratory of Etiology and Epidemiology of Emerging Infectious Diseases in Universities of Shandong, Shandong First Medical University and Shandong Academy of Medical Sciences, Tai'an, China; The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital), Jinan, China. Electronic address: wfshi@sdfmu.edu.cn.
Wenjie TanNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China; Central Theater, People's Liberation Army General Hospital, Wuhan, China; Center for Biosafety Mega-Science, Chinese Academy of Sciences, Beijing, China. Electronic address: tanwj@ivdc.chinacdc.cn.
National Institute for Viral Disease Control and Prevention · CNBGI Group (China) · CNChinese Academy of Sciences · CNShandong First Medical University · CNHubei Provincial Center for Disease Control and Prevention · CNInstitute of Microbiology · CNShandong Provincial QianFoShan Hospital · CNUniversity of Sydney · AUWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn late December, 2019, patients presenting with viral pneumonia due to an unidentified microbial agent were reported in Wuhan, China. A novel coronavirus was subsequently identified as the causative pathogen, provisionally named 2019 novel coronavirus (2019-nCoV). As of Jan 26, 2020, more than 2000 cases of 2019-nCoV infection have been confirmed, most of which involved people living in or visiting Wuhan, and human-to-human transmission has been confirmed.

methodsWe did next-generation sequencing of samples from bronchoalveolar lavage fluid and cultured isolates from nine inpatients, eight of whom had visited the Huanan seafood market in Wuhan. Complete and partial 2019-nCoV genome sequences were obtained from these individuals. Viral contigs were connected using Sanger sequencing to obtain the full-length genomes, with the terminal regions determined by rapid amplification of cDNA ends. Phylogenetic analysis of these 2019-nCoV genomes and those of other coronaviruses was used to determine the evolutionary history of the virus and help infer its likely origin. Homology modelling was done to explore the likely receptor-binding properties of the virus.

findingsThe ten genome sequences of 2019-nCoV obtained from the nine patients were extremely similar, exhibiting more than 99·98% sequence identity. Notably, 2019-nCoV was closely related (with 88% identity) to two bat-derived severe acute respiratory syndrome (SARS)-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21, collected in 2018 in Zhoushan, eastern China, but were more distant from SARS-CoV (about 79%) and MERS-CoV (about 50%). Phylogenetic analysis revealed that 2019-nCoV fell within the subgenus Sarbecovirus of the genus Betacoronavirus, with a relatively long branch length to its closest relatives bat-SL-CoVZC45 and bat-SL-CoVZXC21, and was genetically distinct from SARS-CoV. Notably, homology modelling revealed that 2019-nCoV had a similar receptor-binding domain structure to that of SARS-CoV, despite amino acid variation at some key residues.

interpretation2019-nCoV is sufficiently divergent from SARS-CoV to be considered a new human-infecting betacoronavirus. Although our phylogenetic analysis suggests that bats might be the original host of this virus, an animal sold at the seafood market in Wuhan might represent an intermediate host facilitating the emergence of the virus in humans. Importantly, structural analysis suggests that 2019-nCoV might be able to bind to the angiotensin-converting enzyme 2 receptor in humans. The future evolution, adaptation, and spread of this virus warrant urgent investigation.

fundingNational Key Research and Development Program of China, National Major Project for Control and Prevention of Infectious Disease in China, Chinese Academy of Sciences, Shandong First Medical University.

Indexed as

Genome, ViralBetacoronavirusBronchoalveolar Lavage FluidChinaCoronavirus InfectionsCOVID-19Disease ReservoirsDNA, ViralGenomicsHigh-Throughput Nucleotide SequencingHumansPhylogenyPneumonia, ViralReceptors, VirusSARS-CoV-2Sequence AlignmentDNA, ViralReceptors, Virus

Identifiers

PMID32007145
PMCPMC7159086
OpenAlexW3004318991

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

and 4 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.